Abstract
The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. The cornerstone of treatment is lifestyle modification, encompassing weight reduction and physical exercise. However, pharmacotherapy is usually also required to achieve the recommended target values for the various components of the MetS, such as hypertension, dysglycemia and dyslipidemia. Regarding lipid treatment, statins are the main therapeutic agents while in blood pressure control a significant amount of pathophysiological and clinical evidence would suggest the use, as first line agents, of ACE inhibitors or angiotensin receptor blockers. Metformin seems to be the drug of choice for dysglycemia, specially since recent evidence questions the safety of thiazolidinediones. New drugs, targeting multiple components of the MetS, are under development but no data are currently available regarding their long-term efficacy and safety profile. In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS.
Keywords: Dysglycemia, dyslipidemia, hypertension, hyperuricemia, metabolic syndrome, smoking.
Current Pharmaceutical Design
Title:Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Volume: 20 Issue: 31
Author(s): Ioanna Gouni-Berthold and Heiner K. Berthold
Affiliation:
Keywords: Dysglycemia, dyslipidemia, hypertension, hyperuricemia, metabolic syndrome, smoking.
Abstract: The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. The cornerstone of treatment is lifestyle modification, encompassing weight reduction and physical exercise. However, pharmacotherapy is usually also required to achieve the recommended target values for the various components of the MetS, such as hypertension, dysglycemia and dyslipidemia. Regarding lipid treatment, statins are the main therapeutic agents while in blood pressure control a significant amount of pathophysiological and clinical evidence would suggest the use, as first line agents, of ACE inhibitors or angiotensin receptor blockers. Metformin seems to be the drug of choice for dysglycemia, specially since recent evidence questions the safety of thiazolidinediones. New drugs, targeting multiple components of the MetS, are under development but no data are currently available regarding their long-term efficacy and safety profile. In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS.
Export Options
About this article
Cite this article as:
Gouni-Berthold Ioanna and Berthold K. Heiner, Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome, Current Pharmaceutical Design 2014; 20 (31) . https://dx.doi.org/10.2174/1381612819666131206111721
DOI https://dx.doi.org/10.2174/1381612819666131206111721 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Herbs Effective for Gray Hair in Traditional Persian Medicine
Current Traditional Medicine Subject Index To Volume 4
Current Vascular Pharmacology Meet Our Editorial Board Member
Infectious Disorders - Drug Targets The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
MicroRNA Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews Diabetes and Obesity in Pregnancy: From Patients to Molecular Mechanisms
Current Vascular Pharmacology Occurrence and Biological Properties of Sphingolipids - A Review
Current Nutrition & Food Science Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research The Atherosclerotic Plaque Vulnerability: Focus on the Oxidative and Endoplasmic Reticulum Stress in Orchestrating the Macrophage Apoptosis in the Formation of the Necrotic Core
Current Medicinal Chemistry Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design